首个骨髓保护药:曲拉西利

The first bone marrow protective drug:trilaciclib

骨髓抑制是大多数化疗药物的常见毒性。作为首个骨髓保护药,曲拉西利可使免疫细胞、造血干细胞和祖细胞暂时停滞在细胞周期的G1期,减少其损伤和死亡从而增强免疫反应并降低化疗诱导的骨髓抑制。临床试验结果显示曲拉西利可明显改善化疗患者生存质量,尤其能显著减少疲劳、中性粒细胞减少、贫血和血小板减少症的发生,降低粒细胞集落刺激因子的使用率和输血患者比例。

Myelosuppression is the common toxicity of most chemotherapy drugs.As the first bone marrow protective drug,trilaciclib can reduce injury and death,enhance immune response and reduce chemotherapy-induced myelosuppression through temporarily arresting immune cells,hemopoietic stem cells and progenitor cells in G,phase of cell cycle.The clinical trials have shown that trilaciclib can significantly improve the quality of life of chemotherapy patients,especially reduce the occurrence of fatigue,neutropenia,anemia and thrombocytopenia,and reduce the usage rate of granulocyte colony-stimulating factor and the proportion of patients receiving blood transfusion.